ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
AC Immune SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026
$2.44+0.04 (+1.88%)
Close on Oct 19, 2026
Share price
−$0.46 (−16.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
AC Immune SA saw revenue fall 86.9% to CHF 3.57M over fiscal 2025. Free cash flow was -CHF 70.16M, down 207.5% from a year earlier.
Revenue
CHF 3.57M
-86.9% vs. a year earlier
Operating income
-CHF 69.32M
FY2025
Free cash flow
-CHF 70.16M
-207.5% vs. a year earlier
EPS, diluted
-0.70 CHF
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CHF 3.57M
- EPS, diluted
- -0.70 CHF
- Free cash flow
- -CHF 70.16M
Valuation needs the share price. It fills in once daily prices are connected and converted from CHF.
Twelve years at a glance
Fiscal years 2014 to 2025, CHF
Revenue
CHF 3.57M-86.9% YoY
Operating income
-CHF 69.32M
EPS, diluted
-0.70 CHF
Free cash flow
-CHF 70.16M-207.5% YoY
Reported period